Hypercalcemia of malignancy (HCM) is the most common metabolic complication seen in patients with cancer, and is associated with a high degree of morbidity and mortality. It affects an estimated 2%–30 ...
The authors used Ovid Medline to search for human trials on hypercalcemia and furosemide from 1950 to April 2008, and articles related to bisphosphonates and hypercalcemia during the same period.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results